Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 2/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | TTK | P33981 | 1/20 | 0.32 |
| ▸ | FYN | P06241 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | LPL | P06858 | 1/20 | 0.31 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.30 |
| ▸ | CDK8 | P49336 | 1/20 | 0.30 |
| ▸ | PPARA | Q07869 | 1/20 | 0.30 |
| ▸ | ERN1 | O75460 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL512152 | 0.70 | CYP1A2 (0.46) | — | |
| SCHEMBL21295764 | 0.70 | NOTUM (0.46) | — | |
| SCHEMBL5539585 | 0.70 | NPC1 (0.39) | — | |
| SCHEMBL5539417 | 0.70 | PTGS1 (0.38) | — | |
| SCHEMBL3785401 | 0.70 | TAAR1 (0.46) | — | |
| SCHEMBL7191487 | 0.69 | LPL (0.46) | IMPDH2ADORA2ACNR2CHRM2CHRM4 | |
| SCHEMBL1126802 | 0.69 | ALDH1A1 (0.50) | IMPDH2ADORA2AADORA1TTKFYN | |
| SCHEMBL25036 | 0.68 | — | — | |
| SCHEMBL1521945 | 0.68 | IMPDH2 (0.37) | IMPDH2ADORA2AADORA1TTKFYN | |
| SCHEMBL11542376 | 0.68 | CYP2A6 (0.50) | ADORA2AADORA1FYNLPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070027315-A1 | Substituted 4,5,6,7-tetrahydrobenzthiazol-2-ylamine compounds | GRUENENTHAL GMBH (DE) | 2007-02-01 | — | — | US | claimed |
| US-8816081-B2 | Boron containing perylene monoimides, a process for their production, their use as building blocks for the production of perylene monoimide derivatives, monoimide derivatives and their use in dye-sensitized solar cells | BASF SE (DE) | 2014-08-26 | — | — | US | disclosed |
| US-20120068123-A1 | USE OF PHTHALOCYANINE COMPOUNDS WITH ARYL OR HETARYL SUBSTITUENTS IN ORGANIC SOLAR CELLS | BASF SE (DE) | 2012-03-22 | — | — | US | disclosed |
| US-20110308592-A1 | USE OF SUBSTITUTED PERYLENES IN ORGANIC SOLAR CELLS | BASF SE (DE) | 2011-12-22 | — | — | US | disclosed |
| US-20110203649-A1 | USE OF INDANTHRENE COMPOUNDS IN ORGANIC PHOTOVOLTAICS | BASF SE (DE) | 2011-08-25 | — | — | US | disclosed |
| WO-2011101810-A1 | USE OF INDANTHRENE COMPOUNDS IN ORGANIC PHOTOVOLTAICS | BASF SE (DE) | 2011-08-25 | — | — | WO | disclosed |
| US-20110104306-A1 | NOVEL COMPOSITIONS AND METHODS FOR THE IDENTIFICATION, ASSESSMENT, PREVENTION AND THERAPY OF HUMAN CANCERS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-05-05 | — | — | US | disclosed |
| US-20110021505-A1 | Use of sulfonyl-substituted 2-sulfonylaminobenzoic acid N-phenylamides in the treatment of pain | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| US-7871775-B2 | Compositions and methods for the identification, assessment, prevention and therapy of human cancers | MILLENNIUM PHARMACEUTICALS, INC (US) | 2011-01-18 | — | — | US | disclosed |
| EP-1716128-B1 | SUBSTITUTED 4,5,6,7-TETRAHYDRO-BENZOTHIAZOL-2-YLAMINE COMPOUNDS | GRUENENTHAL GMBH (DE) | 2010-03-31 | — | — | EP | disclosed |
| US-7348347-B2 | Substituted 4,5,6,7-tetrahydrobenzthiazol-2-ylamine compounds | GRUENENTHAL GMBH (DE) | 2008-03-25 | — | — | US | disclosed |
| US-20070027315-A1 | Substituted 4,5,6,7-tetrahydrobenzthiazol-2-ylamine compounds | GRUENENTHAL GMBH (DE) | 2007-02-01 | — | — | US | disclosed |
| EP-1716128-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDRO-BENZOTHIAZOL-2-YLAMINE COMPOUNDS | Grünenthal GmbH (DE) | 2006-11-02 | — | — | EP | disclosed |
| WO-2005077924-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDRO-BENZOTHIAZOL-2-YLAMINE COMPOUNDS | Grünenthal GmbH (DE) | 2005-08-25 | — | — | WO | disclosed |
| WO-1997011951-A1 | FUNGICIDES | ZENECA LIMITED (GB) | 1997-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110203649-A1 | USE OF INDANTHRENE COMPOUNDS IN ORGANIC PHOTOVOLTAICS | ICMT, EPCAM, INF2 | IMPDH2 472/4885ADORA2A 4364/4885ADORA1 4692/4885 |
| US-20110021505-A1 | Use of sulfonyl-substituted 2-sulfonylaminobenzoic acid N-phenylamides in the treatment of pain | SCN1A, SCN2A, CACNA1A | IMPDH2 3491/4885ADORA2A 326/4885ADORA1 172/4885 |
| US-20110104306-A1 | NOVEL COMPOSITIONS AND METHODS FOR THE IDENTIFICATION, ASSESSMENT, PREVENTION AND THERAPY OF HUMAN CANCERS | TSG101, MKI67, TP53 | IMPDH2 1098/4885ADORA2A 3639/4885ADORA1 4034/4885 |
| US-20110308592-A1 | USE OF SUBSTITUTED PERYLENES IN ORGANIC SOLAR CELLS | PPOX, JUP, CRY2 | IMPDH2 1333/4885ADORA2A 1894/4885ADORA1 2989/4885 |
| US-20070027315-A1 | Substituted 4,5,6,7-tetrahydrobenzthiazol-2-ylamine compounds | TPH2, HTR6, TPH1 | IMPDH2 4105/4885ADORA2A 323/4885ADORA1 1081/4885 |
| US-20120068123-A1 | USE OF PHTHALOCYANINE COMPOUNDS WITH ARYL OR HETARYL SUBSTITUENTS IN ORGANIC SOLAR CELLS | RB1, NRAS, HLA-B | IMPDH2 2808/4885ADORA2A 1251/4885ADORA1 1927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.